11 hours ago
Adaptimmune Therapeutics Stock (ADAP) Rockets 50% on CCO Severance Agreement
Adaptimmune Therapeutics (ADAP) stock rocketed higher on Monday after the clinical-stage biopharmaceutical company reached a severance agreement with former Chief Commercial Officer Cintia Piccina. Under the terms of this agreement, Piccina will receive 12 months of pay, $473,800, in a lump-sum payment.
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Piccina will also continue to be able to benefit from the Employee 2016 Share Option Scheme. This will allow her to exercise vested options until January 30, 2032. The former CCO was also permitted a 'period of 12 months from the Separation Date to exercise any other Market Value Options that have vested by the Separation Date.'
Piccina was terminated as the CCO of Adaptimmune Therapeutics on August 8, 2025. The reason for this was redundancy. Piccina's severance agreement with the company will go into effect on August 23,
2025.
Adaptimmune Therapeutics Stock Movement Today
Adaptimmune Therapeutics stock was up 47.23% in pre-market trading on Monday, following an 18.38% fall on Friday. The shares have also decreased 88.98% year-to-date and 94.69% over the past 12 months. Today's news saw heavy trading of ADAP stock, with some 270 million shares traded, compared to a three-month daily average of about 38 million units.
Is Adaptimmune Therapeutics Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts' consensus rating for Adaptimmune Therapeutics is Moderate Sell, based on four Hold and two Sell ratings over the past three months. With that comes an average ADAP stock price target of 35 cents, representing a potential 488.24% upside for the shares.
